Benitec Biopharma Target Price

See Benitec Biopharma's analyst price targets ($21) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$13.78

Average Target Price

$20.50

48.8% upside

2 analysts in the last 4 months

High: $25 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-28	Wedbush	$16	16.1% upside
2026-05-12	Evercore ISI	$25	81.4% upside
2025-11-24	H.C. WainwrightRaghuram Selvaraju	$32	132.2% upside
2025-11-04	H.C. Wainwright	$35	154% upside
2025-11-04	JMP Securities	$22	59.7% upside
2025-09-16	OppenheimerAndreas Argyrides	$29	110.4% upside
2024-10-14	JMP SecuritiesSilvan Tuerkcan	$18	30.6% upside
2024-10-14	JMP SecuritiesSilvan Tuerkcan	$16	16.1% upside
2024-10-14	Leerink PartnersMani Foroohar	$13	5.7% downside
2024-09-24	Piper SandlerYasmeen Rahimi	$30	117.7% upside

Benitec Biopharma (BNTC) FAQ

The latest target price for BNTC is $21. Investors often review this figure alongside Benitec Biopharma's historical trend and sector peers before judging valuation or financial health.

Benitec Biopharma trades near $13.78 while the consensus target sits at $21 (48.8% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting BNTC's target price ($21), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.